Agenus (AGEN)
Develops investigational BOT+BAL antibodies for colorectal cancer and selected tumors.
Something off on this page? Send us feedback.
Develops BOT+BAL, an investigational anti-CTLA-4 and anti-PD-1 antibody combination for colorectal cancer and selected tumors. The clinical-stage immuno-oncology company combines internal development capabilities with selected collaborations and retained manufacturing capacity.
Develops BOT+BAL, an investigational combination of botensilimab, an anti-CTLA-4 antibody, and balstilimab, an anti-PD-1 antibody. The lead program is being developed for colorectal cancer and selected other tumors; neither component is approved for commercial sale.
Discovery and development combine internal translational, clinical, and regulatory work with selected collaborations. Earlier vaccine, adjuvant, and checkpoint-antibody programs inform a portfolio that the company narrowed after its strategic realignment.
Manufacturing flexibility depends on the Zydus collaboration, which provides committed capacity at transferred U.S. biologics facilities. Progress toward registration and commercialization depends on additional capital and regulatory development.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $7 | Target: $25 |
| Jun 4, 2025 | H.C. Wainwright | Upgrade | ||
| Jun 4, 2025 | HC Wainwright & Co. | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.7M · Total debt $40.7M · Total assets $172.7M · Shareholders' equity −$199.1M
- Revenue
- $34.5M
- Operating income
- $11.3M
- Net income
- −$550.0K
No dividends on record.
| Institutions | ≈ 31.93% | 14.38M shares | |
|---|---|---|---|
| 110 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 10.01% | 4.51M shares | |
| 8 holders · as of Sep 15, 2026 | |||
| Strategic holders | 4.74% | 2.13M shares | |
| 1 holder · as of Jan 23, 2026 | |||
| Other | ≈ 53.32% | 24.01M shares | |
| remainder | |||
45.02M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (45.02M in the company's Sep 23, 2026 report, 41.64M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RA Capital Management, L.P.Institution | 9.65% | 4.34M | filed Jul 20, 2026 |
Invus Public Equities, L.P.Insider | 8.82% | 3.97M | filed Jul 17, 2026 |
BlackRock, Inc.Institution | 5.70% | 2.56M | as of Jun 30, 2026 |
Zynext Ventures USA LLCStrategic | 4.74% | 2.13M | filed Jan 23, 2026 |
Vanguard Capital Management LLCInstitution | 3.72% | 1.68M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bristol-Myers Squibb
Approved PD-1 plus CTLA-4 regimen across major solid tumors
- Adagene (ADR)
Masked anti-CTLA-4 doublet in MSS metastatic colorectal cancer
- Merck
Approved PD-1 therapy for MSI-H/dMMR metastatic colorectal cancer
- BioNTech (ADR)
Late-stage CTLA-4 candidate for solid-tumor immunotherapy
- MacroGenics
Phase 2 PD-1×CTLA-4 bispecific under a partial clinical hold
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Agenus | $8.50 | −2.30% | $362.3M | 3.3 | — | 2.7 | +34.3% |
| Bristol-Myers Squibb | $61.76 | −0.79% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Adagene (ADR) | $3.01 | −6.92% | $121.6M | — | — | 13.1 | — |
| Merck | $147.38 | −2.34% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| BioNTech (ADR) | $99.53 | −1.33% | $25.34B | — | — | 8.4 | −60.7% |
| MacroGenics | $3.89 | −5.70% | $261.9M | — | — | 1.6 | +47.6% |
| Median | 67.2 | 13.4 | 5.6 | +5.4% |